KS-KCAS
12.9.2022 12:04:33 CEST | Business Wire | Press release
KCAS Bioanalytical and Biomarker Services (KCAS), a leading bioanalytical contract research organization (CRO), backed by Vitruvian Partners, closed the purchase of Active Biomarkers, located in Lyon, France. Active Biomarkers is a renowned assay development and specialty bioanalytical laboratory with expertise in oncology, infectious disease, inflammation and neurodegenerative disorders. Financial terms were not disclosed. Formerly owned by its management team and Turenne Santé fund, Active Biomarkers operates in a new, state-of-the-art facility in Lyon, France with significant expansion opportunities. This transaction adds valuable bioassay and cellular analysis expertise as well as European capacity to support customers globally as KCAS continues to advance its mission of providing high quality bioassay services to the biotech and pharmaceutical industries. The acquisition of Active Biomarkers is the second in 2022 by KCAS. FlowMetric, a leading flow cytometry and cellular analysis CRO, joined KCAS in early 2022. The Lyon site adds to KCAS and FlowMetric’s existing facilities in Kansas, Philadelphia and Milan, Italy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220912005063/en/
Active Biomarkers building in Lyon, France (Photo: Business Wire)
John Bucksath, CEO of KCAS, stated “We are delighted to partner with the Active Biomarkers team, accelerating our combined offering to support the customers we serve globally. The combined expertise and capacity of KCAS, FlowMetric, and Active Biomarkers is unique. The high-quality, science-first and client-centric culture we all share is key to our commitment to become the CRO partner of choice for the global pharma and biopharma industries. KCAS has embarked on significant investments, including a purpose-built 70,000 sq. ft. facility in Kansas City and a 26,000 sq. ft. facility in Pennsylvania, and accelerating our international footprint through acquisitions. We continue to attract the industry’s top scientific talent and focus on outstanding science and customer service. With our investors, Vitruvian Partners, we are optimally positioned to invest in our people and deliver world-class services for our growing client base. The acquisition of Active Biomarkers gives our combined clients access to further scientific expertise and support in both markets regionally and internationally.”
Marc Essodaigui, CEO of Active Biomarkers, comments, “Our entire team is thrilled about the new partnership with KCAS and the combined organizations’ outlook. This combination will allow us to provide even more comprehensive, best-in-class services for the biopharma and life sciences sector. The KCAS’ alliance, backed by a leading world-class growth investor, will provide us with the support and growth to expand our technological expertise, capacity, and geographical footprint.”
Sophie Bower-Straziota, Partner at Vitruvian Partners, comments, “Active Biomarkers has built a strong reputation in Europe founded in scientific excellence. The company fits with our investment strategy of backing best-in-class operations offering services to a market with strong tailwinds and internationalization opportunities. The acquisition of Active Biomarkers by KCAS builds on the excellent foundation KCAS has built in the US and supports the increasingly international needs of the company’s growing pharmaceutical and biotech clients. As the drug development market continues to evolve, we will continue to support investment in scientific capabilities, broadening geographical reach, providing the resources to scale the business, and making strategic acquisitions.”
About KCAS - KCAS is a rapidly growing company that provides comprehensive GLP compliant development services from early discovery support through product registration and beyond. One of only a select few CROs offering both large and small molecule development with extensive capabilities and expertise, KCAS provides a truly differentiated approach to its clients who are looking for both scientific expertise and excellent customer service. KCAS is headquartered in Olathe, Kansas – the Kansas City metro area and employs more than 300 employees. Website: KCASBio.com.
About Active Biomarkers – Founded in 2011, Active Biomarkers is an integrated bioanalytical laboratory offering a wide range of services, including PK, immunogenicity, soluble and cellular biomarker analyses for clinical studies. Operating in state-of-the-art BSL2 facilities, GCLP accredited and ISO 9001:2015 certified, the company has a unique track-record in the development, validation, and implementation of analytical methods. Its expert team has supported hundreds of studies in multiple therapeutic areas: oncology, infectious diseases, inflammatory pathologies, and neurodegenerative diseases. Beyond its state-of the-art flow cytometry and ELISpot capabilities, Active Biomarkers offers the broadest panel of immunoassay technologies in Europe, ranging from standard ELISA to multiplexed methods such as Luminex, SP-X or ELLA systems, or ultra-sensitive technologies such as MSD, Gyrolab or Simoa HD-X platforms. Website: active-biomarkers.com
About Vitruvian - Vitruvian is a leading international growth investor headquartered in London with additional offices in Stockholm, Madrid, Munich, Luxembourg, San Francisco, Singapore and Shanghai. Vitruvian focuses on dynamic situations characterized by rapid growth and change across industries. Vitruvian has backed over 90 companies and has assets under management of approximately €10 billion. Website: vitruvianpartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005063/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 14:00:00 CEST | Press release
Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom